“…Tests can be run individually or in a customisable battery to enable users to test a series of participants on a set sequence of tests (Cambridge Cognition Ltd, 2012). The CANTAB has been utilised extensively in the study of various populations, including those with schizophrenia (Levaux et al, 2007), Parkinson's disease (Foltynie, Brayne, Robbins, & Barker, 2004), Huntington's disease , frontal and temporal lobe excisions (Owen, Roberts, Polkey, Sahakian, & Robbins, 1991) and normal functioning adults (De Luca, Wood, Anderson, & Buchanan, 2003;Robbins et al, 1998) The construct validity of CANTAB has been largely based upon the ability of test measures to discriminate between normal adults and various clinical populations, including mild cognitive impairment (Klekociuk, Summers, Vickers, & Summers, 2014;Saunders & Summers, 2010), Alzheimer's disease (Saunders & Summers, 2010), epilepsy (Torgersen, Johan, Hans, Bernt, & Arne, 2012), ADHD (Gau & Shang, 2010) and various central nervous system diseases (Roque, Teixeira, Zachi, & Ventura, 2011). Despite its widespread application and ability to discriminate between clinical and normal functioning groups, the association between established neuropsychological measures and CANTAB components remains under-researched.…”